Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients

NCT02314637 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

240

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Teneligliptin
DRUG: Teneligliptin + Sulfonylurea

Sponsor

Tanabe Pharma Corporation